Berutti Aaron
Known title: SVP, SalesCIK: 0001871334
Berutti Aaron's purchase track record
Berutti Aaron has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/21/2022 | TMCI | $40K | +0.5% | +23.6% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TMCI | ▼ Sell | Tax Withholding | 4,907 | $0 | 8/9/2025 | View on chart |
| TMCI | ▼ Sell | Tax Withholding | 1,815 | $0 | 3/10/2025 | View on chart |
| TMCI | ▼ Sell | Tax Withholding | 728 | $0 | 3/8/2025 | View on chart |
| TMCI | ▲ Buy | Grant | 75,000 | $0 | 1/22/2025 | View on chart |
| TMCI | ▼ Sell | Tax Withholding | 4,821 | $0 | 1/10/2025 | View on chart |
| TMCI | ▲ Buy | Grant | 60,450 | $0 | 8/9/2024 | View on chart |
| TMCI | ▼ Sell | Tax Withholding | 1,815 | $0 | 3/10/2024 | View on chart |
| TMCI | ▼ Sell | Tax Withholding | 711 | $0 | 3/8/2024 | View on chart |
| TMCI | ▲ Buy | Grant | 65,025 | $0 | 1/10/2024 | View on chart |
| TMCI | ▲ Buy | Grant | 29,800 | $0 | 3/10/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 733 | $18K | 3/9/2023 | View on chart |
| TMCI | ▲ Buy | Open Market | 1,825 | $40K | 11/21/2022 | View on chart |
| TMCI | ▲ Buy | Grant | 11,950 | $0 | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.